SCHEMBL15041472

SCHEMBL15041472

Cc1cc(C2CCN(C(C)O)CC2)cnc1-c1cc2cnc(Nc3ccc(OC4CCN(C)CC4)cc3)nc2n(C2CCOC2)c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 1/20 0.40
PAK4 O96013 1/20 0.39
PKN1 Q16512 1/20 0.39
TNK2 Q07912 5/20 0.37
SRC P12931 1/20 0.37
CDK2 P24941 5/20 0.37
CCNA2 P20248 4/20 0.37
CCNA1 P78396 1/20 0.37
FGFR1 P11362 2/20 0.37
CDK4 P11802 2/20 0.37
CCND1 P24385 2/20 0.37
PIK3CD O00329 1/20 0.37
PRKAB2 O43741 1/20 0.37
NUAK1 O60285 1/20 0.37
CCNT1 O60563 1/20 0.37
ABL1 P00519 1/20 0.37
FYN P06241 1/20 0.37
CDK1 P06493 1/20 0.37
CSF1R P07333 1/20 0.37
RET P07949 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15035114 0.95 PAK4 (0.40) CAMK2DPAK4PKN1TNK2SRC
SCHEMBL15785236 0.94 PAK4 (0.43) CAMK2DPAK4PKN1TNK2SRC
SCHEMBL14693028 0.91 PAK4 (0.39) CAMK2DPAK4PKN1TNK2SRC
SCHEMBL14682061 0.90 CAMK2D (0.40) CAMK2DPAK4PKN1TNK2SRC
SCHEMBL13553805 0.89 PAK4 (0.41) CAMK2DPAK4PKN1TNK2SRC
SCHEMBL15041499 0.85 CAMK2D (0.40) CAMK2DPAK4PKN1TNK2SRC
SCHEMBL15785219 0.72 FGFR1 (0.37) CAMK2DSRCCDK2CCNA2CCNA1
SCHEMBL15036466 0.72 CDK4 (0.52) CAMK2DPAK4PKN1CDK2CCNA2
SCHEMBL13553895 0.71 CDK4 (0.45) CDK2CCNA2CCNA1FGFR1CDK4
SCHEMBL15041527 0.71 SRC (0.40) CAMK2DPAK4PKN1TNK2SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 CAMK2D 469/4885PAK4 5/4885PKN1 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.